Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 330,077,952
  • Shares Outstanding, K 2,710,890
  • Annual Sales, $ 71,890 M
  • Annual Income, $ 16,540 M
  • 36-Month Beta 0.80
  • Price/Sales 4.60
  • Price/Cash Flow 14.72
  • Price/Book 4.71

Price Performance

See More
Period Period Low Period High Performance
1-Month
120.95 +1.60%
on 04/18/17
126.14 -2.58%
on 03/27/17
-2.59 (-2.06%)
since 03/24/17
3-Month
110.76 +10.95%
on 01/25/17
129.00 -4.74%
on 03/15/17
+11.13 (+9.96%)
since 01/24/17
52-Week
109.32 +12.41%
on 12/07/16
129.00 -4.74%
on 03/15/17
+9.57 (+8.45%)
since 04/22/16

Most Recent Stories

More News
Johnson & Johnson to Host Pharmaceutical Business Review

Johnson & Johnson (NYSE: JNJ) will host a review of its Pharmaceutical businesses for the investment community beginning at 8:30 a.m. (Eastern Time) on Wednesday, May 17, 2017 at the Hyatt Regency Hotel...

JNJ : 122.89 (+0.93%)
Is Pain Ahead for Healthcare ETFs After Weak JNJ Q1?

Results from Johnson and Johnson could be a warning sign for other drug makers, which are scheduled to report this week and the next.

VHT : 137.82 (+0.96%)
JNJ : 122.89 (+0.93%)
MRK : 62.14 (+0.40%)
IYH : 156.20 (+0.96%)
FHLC : 35.80 (+0.96%)
ABBV : 64.66 (+1.32%)
AMG : 166.45 (+1.92%)
GILD : 66.25 (+0.49%)
SPY : 237.17 (+1.10%)
AMGN : 163.14 (+1.70%)
PFE : 33.74 (+0.30%)
BMY : 53.55 (+0.13%)
Is Pain Ahead for Healthcare ETFs After Weak JNJ Q1?

Results from Johnson and Johnson could be a warning sign for other drug makers, which are scheduled to report this week and the next.

VHT : 137.82 (+0.96%)
JNJ : 122.89 (+0.93%)
MRK : 62.14 (+0.40%)
IYH : 156.20 (+0.96%)
FHLC : 35.80 (+0.96%)
ABBV : 64.66 (+1.32%)
AMG : 166.45 (+1.92%)
GILD : 66.25 (+0.49%)
SPY : 237.17 (+1.10%)
AMGN : 163.14 (+1.70%)
PFE : 33.74 (+0.30%)
BMY : 53.55 (+0.13%)
Britain's back in favor for corporate deals despite Brexit

LONDON (AP) — Britain has reclaimed its place as one of the top five countries that firms look to make deals in, just six months after dropping off the list in the wake of the country's surprise to leave...

JNJ : 122.89 (+0.93%)
Dow 30 Stock Roundup: AmEx, UNH Beat; Goldman, JNJ, Verizon Disappoint

The index experienced a volatile week, guided by geopolitical events, earnings and oil prices.

VZ : 47.05 (-0.42%)
IBM : 160.75 (+0.23%)
JPM : 87.50 (+3.53%)
JNJ : 122.89 (+0.93%)
AXP : 80.45 (+1.08%)
TRV : 120.57 (+1.23%)
GS : 223.22 (+2.93%)
UNH : 172.33 (+0.68%)
FDA approves 2nd near-copy of Remicade for immune disorders

Federal regulators on Friday approved another alternative version of Remicade, an expensive injected drug widely used for rheumatoid arthritis and other immune system disorders.

JNJ : 122.89 (+0.93%)
MRK : 62.14 (+0.40%)
PFE : 33.74 (+0.30%)
What's in Store for AbbVie (ABBV) this Earnings Season?

AbbVie Inc. (ABBV) is slated to release first-quarter 2017 earnings, before the opening bell on Apr 27.

RARE : 61.31 (+1.22%)
PTI : 5.48 (-4.53%)
JNJ : 122.89 (+0.93%)
ABBV : 64.66 (+1.32%)
Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL

Key highlights from the pharma sector include J&J's (JNJ) first quarter results and a CRL for Lilly's RA drug.

JNJ : 122.89 (+0.93%)
LLY : 83.42 (+1.87%)
AGN : 236.98 (+0.27%)
NVS : 74.61 (+1.65%)
RHHBY : 32.0100 (+1.30%)
SNY : 45.90 (+4.11%)
BMY : 53.55 (+0.13%)
AbbVie's (ABBV) Cancer Candidate Fails in Phase III Studies

AbbVie Inc. announced disappointing top-line results from two phase III studies evaluating veliparib in combination with chemotherapy for treatment of patients with squamous non-small cell lung cancer...

AZN : 30.24 (+1.61%)
JNJ : 122.89 (+0.93%)
ABBV : 64.66 (+1.32%)
PFE : 33.74 (+0.30%)
4 Sell-Ranked Drug Stocks Investors Should Avoid Ahead of Earnings

Here is a look at four Sell-Ranked drug stocks with negative earnings ESP that should be avoided ahead of earnings.

TECH : 103.14 (+1.36%)
DRNA : 2.98 (+1.36%)
VYGR : 10.32 (-0.19%)
JNJ : 122.89 (+0.93%)
VRX : 8.60 (+1.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Support & Resistance

2nd Resistance Point 123.81
1st Resistance Point 123.35
Last Price 122.89
1st Support Level 122.29
2nd Support Level 121.69

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.